X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Impilo is advancing its Tumor-Penetrating Nanocomplex platform, to provide a targeted delivery approach for a wide range of nucleic acid treatment modalities including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) for solid tumor. cancer indications.
Lead Product(s): Nucleic Acid-based Medicine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
CendR Platform combines Cend’s clinical-stage targeted tumor penetrating peptide, CEND-1. The combination expands Cend’s drug delivery capabilities to create a unique platform for targeted tissue penetrating delivery of nucleic acid-based medicines to solid tumor cancers.
Lead Product(s): siRNA
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cend Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition September 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
